Holen Sie sich die Stockscreener-App
84.75
2.08%
1.73
Handel nachbörslich:
83.99
-0.76
-0.90%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$83.02
Offen:
$82.49
24-Stunden-Volumen:
4.58M
Relative Volume:
0.83
Marktkapitalisierung:
$32.70B
Einnahmen:
$4.82B
Nettoeinkommen (Verlust:
$930.40M
KGV:
36.25
EPS:
2.3381
Netto-Cashflow:
$1.43B
1W Leistung:
+1.56%
1M Leistung:
+15.20%
6M Leistung:
+21.12%
1J Leistung:
+10.93%
1-Tages-Spanne:
$82.09
$85.06
1-Wochen-Bereich:
$82.09
$87.85
52-Wochen-Spanne:
$54.11
$87.85
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
84.75 | 28.31B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
107.81 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
339.03 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
87.16 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.31 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.72 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
Dexcom Inc (DXCM) Institutional Confidence - TradingKey
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders - TradingView
DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion - TradingView
Dexcom stock trades near 52-week high as continuous glucose monitoring growth supports valuation - Ad-hoc-news.de
Dexcom Inc (DXCM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dexcom Inc (DXCM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dexcom Inc (DXCM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dexcom Selected as First Manufacturer in FDA's Innovative Digital Health Outcomes Program - HCI Innovation Group
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dexcom Inc (DXCM) Balance Sheet - TradingKey
Dexcom stock trades steady as glucose-monitoring growth supports valuation - Ad-hoc-news.de
Dexcom Inc|Price:71.540|Chg%:+1.060 - TradingKey
Does DexCom’s (DXCM) Longer-Wear G7 Approval Hint At A Durable Edge In Connected Diabetes Care? - simplywall.st
Dexcom stock trades near recent highs as diabetes tech growth supports valuation - AD HOC NEWS
FDA selects Dexcom as first participant in TEMPO pilot for digital health devices - MedTech World
DexCom Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
DXCM|Dexcom Inc|Price:73.585|Chg%:+2.045 - TradingKey
Dexcom Gets First Slot In FDA-CMS Pilot That Rewards Real-World Data At Scale - insights.citeline.com
Dexcom Inc (DXCM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
FDA names Dexcom as first participant in digital health pilot - MedTech Dive
DexCom (DXCM) Earnings Expected to Grow: Should You Buy? - Yahoo Finance Singapore
Dexcom Kicks Off FDA’s TEMPO Digital Health Device Pilot - Medical Product Outsourcing
Dexcom Inc (DXCM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dexcom (DXCM) Chosen as First Participant in FDA's TEMPO Pilot - GuruFocus
Dexcom stock trades near record levels as glucose monitoring demand supports growth - Ad-hoc-news.de
Dexcom (DXCM) Selected for FDA's TEMPO Pilot Program to Enhance Glucose Monitoring - GuruFocus
DexCom, Inc.'s Stock Price Drops to $71.43, Marking a 4.44% Decrease: Uncovering the Reasons Behind the Downfall - Smartkarma
A Look at DexCom Inc (DXCM) After 4.4% Decline -- GF Value $104.58 vs Price $71.43 - GuruFocus
A Look at DexCom Inc (DXCM) After 4.4% Decline -- GF Value $104. - GuruFocus
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program - Dexcom Investor Relations
DexCom Inc. stock underperforms Wednesday when compared to competitors - MSN
At US$74.75, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List? - Moomoo
Dexcom Selected as First Participant in FDA's TEMPO Pilot Program - Intellectia AI
Dexcom Executive Chair Kevin R. Sayer Disposes of 26,756 Shares via Prearranged Rule 10b5-1 Plan - Kalkine Media
Dexcom Inc (DXCM) chair Kevin Sayer sells 26,756 shares under 10b5-1 plan - Stock Titan
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
Dexcom stock trades near 52-week high as G7 CGM growth supports earnings momentum - AD HOC NEWS
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) executive plans 26,756-share stock sale - Stock Titan
Dexcom stock trades steady as diabetes CGM growth supports earnings outlook - Ad-hoc-news.de
Dexcom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MSN
Dexcom stock holds steady as investors weigh Q1 2026 growth - ad-hoc-news.de
Enterprise value to EBIT forward of DexCom, Inc. – FWB:DC4 - TradingView
DexCom (DXCM) Back In Focus As Canada Approval Tests Its Valuation - Sahm
Dexcom stock trades steady as diabetes technology growth supports valuation - ad-hoc-news.de
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom Inc. Stock Climbs 7.2%, Outperforms Market - webull.com
DXCM5813816 Bond Profile — Key Metrics - TradingView
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dexcom Inc-Aktie (DXCM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jul 31 '26 |
Sale |
80.00 |
2,000 |
160,000 |
50,852 |
2.08%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):